Basic information
Biomarker: ANXA2
Histology type: endometrioid endometrial carcinoma
Stage: low risk
Cohort characteristics
Country: Spain/USA/Norway
Region: Lleida/Santiago de Compostela/Barcelona/Madrid/Barcelona/Sevilla/Boston/New York/Bergen
Followed up time :
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 279 | Fresh frozen tumor tissue tumor samples primary tumors and recurrences | 12 | formalin-fixed, paraffinembedded (FFPE) tumor tissue (115 primary tumors and 25 post-radiation recurrences) | 140 | FFPE tumor tissue samples from 131 patients with primary endometrial carcinoma | 93 | peripheral blood samples Grade 3 Stage IB carcinomas to metastatic Stage IV carcinomas and recurrences | 34 |
Sample information
Conclusion: Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer.ANXA2 demonstrated a predictive value also among low risk Stage I endometrioid endometrial carcinomas, highlighting the clinical utility of ANXA2 biomarker as predictor of recurrent disease in endometrial cancer.
Sample type : tissue
Sample method: immunohistochemistry/RT-q-PCR
Expression pattern : expression(threshold>190)
Expression elevation: Cytoplasmic and heterogeneous immunohistochemical staining was semi-quantitatively graded based on the percentage and on the intensity of the labelling. Histological scores (derived from the mean between two cylinders) ranged from 0 (no immunoreaction) to 300 (maximum immunoreactivity) by applying the formula: Histoscore =1× (% light staining)+ 2× (% moderate staining)+ 3× (% strong staining).
Disease information
Related information
Funtion Uniprot: Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress response. Inhibits PCSK9-enhanced LDLR degradation, probably reduces PCSK9 protein levels via a translational mechanism but also competes with LDLR for binding with PCSK9 (PubMed:18799458, PubMed:24808179, PubMed:22848640).
UniProt ID: P07355
UniProt Link: https://www.uniprot.org/uniprotkb/P07355/entry
Biological function from UniProt: #Host-virus interaction
Molecular function from UniProt:
Subcellular UniProt: #Basement membrane #Extracellular matrix #Secreted
Alternative name from UniProt:
Miscellaneous: It may cross-link plasma membrane phospholipids with actin and the cytoskeleton and be involved with exocytosis.
Recommended name: Annexin A2
Gene name from HGNC: ANXA2 (ANX2, ANX2L4, CAL1H, LIP2, LPC2D)
HPA class: Cancer-related genes FDA approved drug targets Plasma proteins Transporters
AlphaFold DB: P07355
AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P07355
HPA link: https://www.proteinatlas.org/ENSG00000182718-ANXA2
Tissue specificity RNA from HPA: Tissue enhanced (esophagus)
Tissue expression from HPA: Ubiquitous membranous and extracellular expression.
Single cell type specificity Cell type enhanced (Basal respiratory cells, Pancreatic endocrine cells, Prostatic glandular cells, Urothelial cells)
Immune cell specificity: Group enriched (basophil, myeloid DC, classical monocyte, non-classical monocyte, intermediate monocyte, T-reg)
Subcellular summary HPA Located in Plasma membrane, Cytosol
Cancer prognostic summary HPA Prognostic marker in renal cancer (unfavorable), pancreatic cancer (unfavorable), liver cancer (unfavorable), urothelial cancer (unfavorable), endometrial cancer (favorable) and lung cancer (unfavorable)
Pathology link: https://www.proteinatlas.org/ENSG00000182718-ANXA2/pathology
Pathology endo: https://www.proteinatlas.org/ENSG00000182718-ANXA2/pathology/endometrial+cancer
OMIM: 151740
OMIM link2: https://www.omim.org/entry/151740
HGNC ID: HGNC:537
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:537
